share_log

微創醫療：上海微創心脈醫療科技（集團）股份有限公司截至二零二三年十二月三十一日止十二個月未經審核財務資料

MICROPORT: UNAUDITED FINANCIAL INFORMATION OF SHANGHAI MICROPORT ENDOVASCULAR MEDTECH (GROUP) CO., LTD. FOR THE TWELVE MONTHS ENDED 31 DECEMBER 2023

香港交易所 ·  Feb 23 09:00
Summary by Moomoo AI
微創醫疗科學有限公司（微創醫疗）旗下子公司上海微創心脈醫療科技（心脈醫療科技）公布了截至2023年12月31日止十二個月的未經審核財務資料。數據顯示，心脈醫療科技的收入、利潤總額及歸屬於其股權持有人的淨利潤分別同比增長32.43%、38.26%及37.98%。總資產及歸屬於心脈醫療科技股權持有人的總權益亦分別增加112.62%及123.65%。微創醫疗持有心脈醫療科技40.32%的股權，並將其業績合併入本公司財務報表。投資者應注意，上述財務數據僅反映心脈醫療科技的業務表現，未經審核，且不代表微創醫疗整體業務狀況。微創醫療於2024年2月23日由常兆華博士主席發布此公告。
微創醫疗科學有限公司（微創醫疗）旗下子公司上海微創心脈醫療科技（心脈醫療科技）公布了截至2023年12月31日止十二個月的未經審核財務資料。數據顯示，心脈醫療科技的收入、利潤總額及歸屬於其股權持有人的淨利潤分別同比增長32.43%、38.26%及37.98%。總資產及歸屬於心脈醫療科技股權持有人的總權益亦分別增加112.62%及123.65%。微創醫疗持有心脈醫療科技40.32%的股權，並將其業績合併入本公司財務報表。投資者應注意，上述財務數據僅反映心脈醫療科技的業務表現，未經審核，且不代表微創醫疗整體業務狀況。微創醫療於2024年2月23日由常兆華博士主席發布此公告。
Shanghai Micro-Chung Cardiac Medical Technology (Cardiac Medical Technology), a subsidiary of MicroChung Medical Sciences Limited (MicroChung Medical Technology), announced unaudited financial data for the twelve months ended December 31, 2023. Data showed that Cardiac Medical Technology's revenue, total profit and net profit attributable to its equity holders grew by 32.43%, 38.26% and 37.98%, respectively. Total assets and shareholders' equity of Cardiac Medical Technology also increased by 112.62% and 123.65%, respectively. MicroVenture Medical owns 40.32% of Cardiac Medical Technology and incorporates its results into the company's financial statements. Investors should note that the above financial data only reflects the business performance of Cardiac Medical Technology, is unaudited, and does not represent the overall business performance of Micro Medical. Micro-Chung Medical issued this announcement on 23 February 2024 by Dr. Chang Chiu Wah, Chairman.
Shanghai Micro-Chung Cardiac Medical Technology (Cardiac Medical Technology), a subsidiary of MicroChung Medical Sciences Limited (MicroChung Medical Technology), announced unaudited financial data for the twelve months ended December 31, 2023. Data showed that Cardiac Medical Technology's revenue, total profit and net profit attributable to its equity holders grew by 32.43%, 38.26% and 37.98%, respectively. Total assets and shareholders' equity of Cardiac Medical Technology also increased by 112.62% and 123.65%, respectively. MicroVenture Medical owns 40.32% of Cardiac Medical Technology and incorporates its results into the company's financial statements. Investors should note that the above financial data only reflects the business performance of Cardiac Medical Technology, is unaudited, and does not represent the overall business performance of Micro Medical. Micro-Chung Medical issued this announcement on 23 February 2024 by Dr. Chang Chiu Wah, Chairman.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more